Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)-Reference-Cited by-同舟云学术

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)

Published:2017-10 Issue: Volume:84 Page:262-269
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Modest D.P.,Ricard I.,Stintzing S.,Fischer von Weikersthal L.,Decker T.,Kiani A.,Vehling-Kaiser U.,Al-Batran S.-E.,Heintges T.,Kahl C.,Seipelt G.,Kullmann F.,Scheithauer W.,Moehler M.,Westphalen C.B.,Holch J.W.,von Einem J.C.,Held S.,Heinemann V.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial;Stintzing;Lancet Oncol,2016

3. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer;Modest;J Clin Oncol,2015

4. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study;Cremolini;Lancet Oncol,2015

5. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status;Van Cutsem;J Clin Oncol,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multimodal Therapy Versus Primary Surgery for Gastric and Gastroesophageal Junction Diffuse Type Carcinoma, with a Focus on Signet Ring Cell Carcinoma: A Nationwide Study;Annals of Surgical Oncology;2023-12-21

2. Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001);Frontiers in Oncology;2023-09-01

3. Differential Analyses of Peripheral Blood Parameters in CCR5 Inhibition-treated Colorectal Cancer Patients Reveal Dynamic Changes Linked to Clinical Outcomes;Anticancer Research;2020-12

4. Onkologische Therapiekonzepte bei systemischer Metastasierung des kolorektalen Karzinoms;Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie;2019-06

5. Treatment sequencing in metastatic colorectal cancer;European Journal of Cancer;2019-03